These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36043503)

  • 21. The Transition-State Structure for Human MAT2A from Isotope Effects.
    Firestone RS; Schramm VL
    J Am Chem Soc; 2017 Oct; 139(39):13754-13760. PubMed ID: 28880543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.
    Strekalova E; Malin D; Weisenhorn EMM; Russell JD; Hoelper D; Jain A; Coon JJ; Lewis PW; Cryns VL
    Breast Cancer Res Treat; 2019 May; 175(1):39-50. PubMed ID: 30712196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.
    Kalliokoski T; Kettunen H; Kumpulainen E; Kettunen E; Thieulin-Pardo G; Neumann L; Thomsen M; Paul R; Malyutina A; Georgiadou M
    Bioorg Med Chem Lett; 2023 Oct; 94():129450. PubMed ID: 37591318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells.
    Chen H; Xia M; Lin M; Yang H; Kuhlenkamp J; Li T; Sodir NM; Chen YH; Josef-Lenz H; Laird PW; Clarke S; Mato JM; Lu SC
    Gastroenterology; 2007 Jul; 133(1):207-18. PubMed ID: 17631143
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine.
    Alam M; Shima H; Matsuo Y; Long NC; Matsumoto M; Ishii Y; Sato N; Sugiyama T; Nobuta R; Hashimoto S; Liu L; Kaneko MK; Kato Y; Inada T; Igarashi K
    J Biol Chem; 2022 Jul; 298(7):102084. PubMed ID: 35636512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methionine adenosyltransferases in cancers: Mechanisms of dysregulation and implications for therapy.
    Maldonado LY; Arsene D; Mato JM; Lu SC
    Exp Biol Med (Maywood); 2018 Jan; 243(2):107-117. PubMed ID: 29141455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Series of Pyrrolopyridone MAT2A Inhibitors.
    Atkinson SJ; Bagal SK; Argyrou A; Askin S; Cheung T; Chiarparin E; Coen M; Collie IT; Dale IL; De Fusco C; Dillman K; Evans L; Feron LJ; Foster AJ; Grondine M; Kantae V; Lamont GM; Lamont S; Lynch JT; Nilsson Lill S; Robb GR; Saeh J; Schimpl M; Scott JS; Smith J; Srinivasan B; Tentarelli S; Vazquez-Chantada M; Wagner D; Walsh JJ; Watson D; Williamson B
    J Med Chem; 2024 Mar; 67(6):4541-4559. PubMed ID: 38466661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine.
    Martínez-Chantar ML; Latasa MU; Varela-Rey M; Lu SC; García-Trevijano ER; Mato JM; Avila MA
    J Biol Chem; 2003 May; 278(22):19885-90. PubMed ID: 12660248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis.
    Wang X; Guo X; Yu W; Li C; Gui Y; Cai Z
    BMC Cancer; 2014 Mar; 14():196. PubMed ID: 24636201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy.
    Faridoon ; Zheng J; Zhang T; Tong S; Liu T; Cui J; Xu H; Hu D; Shen Y; Yin Y; Zhao D; Tan C; Dong X; Chen J; Ji F; Tong C; Li JJ; Li J; Zhang G
    J Med Chem; 2024 Jun; 67(11):9431-9446. PubMed ID: 38818879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a Sonically Activated Degrader of Methionine Adenosyltransferase 2A by an
    He H; Wang Z; Peng X; Qing L; Zhang Y; Fu S; Xu J; Li Y; Zhang S
    J Med Chem; 2024 Jan; 67(1):543-554. PubMed ID: 38166392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors.
    Chen S; Hou J; Jaffery R; Guerrero A; Fu R; Shi L; Zheng N; Bohat R; Egan NA; Yu C; Sharif S; Lu Y; He W; Wang S; Gjuka D; Stone EM; Shah PA; Rodon Ahnert J; Chen T; Liu X; Bedford MT; Xu H; Peng W
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39313308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
    Kryukov GV; Wilson FH; Ruth JR; Paulk J; Tsherniak A; Marlow SE; Vazquez F; Weir BA; Fitzgerald ME; Tanaka M; Bielski CM; Scott JM; Dennis C; Cowley GS; Boehm JS; Root DE; Golub TR; Clish CB; Bradner JE; Hahn WC; Garraway LA
    Science; 2016 Mar; 351(6278):1214-8. PubMed ID: 26912360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extracellular 5'-methylthioadenosine inhibits intracellular symmetric dimethylarginine protein methylation of FUSE-binding proteins.
    Tang B; Lee HO; Gupta S; Wang L; Kurimchak AM; Duncan JS; Kruger WD
    J Biol Chem; 2022 Sep; 298(9):102367. PubMed ID: 35963436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S-Adenosylmethionine Synthesis Is Regulated by Selective N
    Shima H; Matsumoto M; Ishigami Y; Ebina M; Muto A; Sato Y; Kumagai S; Ochiai K; Suzuki T; Igarashi K
    Cell Rep; 2017 Dec; 21(12):3354-3363. PubMed ID: 29262316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Potent and Oral Bioavailable MAT2A Inhibitors for the Treatment of MTAP-Deleted Tumors.
    Li Q; Zang Y; An D; Liu L; Jiang W; Liu R; Su J; Yang J; Li L; Zhang X
    ACS Med Chem Lett; 2023 Dec; 14(12):1876-1881. PubMed ID: 38116423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of promoter methylation in increased methionine adenosyltransferase 2A expression in human liver cancer.
    Yang H; Huang ZZ; Zeng Z; Chen C; Selby RR; Lu SC
    Am J Physiol Gastrointest Liver Physiol; 2001 Feb; 280(2):G184-90. PubMed ID: 11208539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human Mat2A Uses an Ordered Kinetic Mechanism and Is Stabilized but Not Regulated by Mat2B.
    Bailey J; Douglas H; Masino L; de Carvalho LPS; Argyrou A
    Biochemistry; 2021 Nov; 60(47):3621-3632. PubMed ID: 34780697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.
    Wang Y; Muylaert C; Wyns A; Vlummens P; De Veirman K; Vanderkerken K; Zaal E; Berkers C; Moreaux J; De Bruyne E; Menu E
    Haematologica; 2024 Jan; 109(1):256-271. PubMed ID: 37470139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A.
    Zhang W; Sviripa V; Chen X; Shi J; Yu T; Hamza A; Ward ND; Kril LM; Vander Kooi CW; Zhan CG; Evers BM; Watt DS; Liu C
    ACS Chem Biol; 2013 Apr; 8(4):796-803. PubMed ID: 23363077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.